Navigation Links
New clinical trial to test novel approach to treat triple-negative breast cancer
Date:6/2/2011

Baltimore, MD -- A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women. The study will help researchers determine if an experimental drug, entinostat, can reprogram tumor cells to express a protein called an estrogen receptor to make them sensitive to hormone therapy.

Saranya Chumsri, M.D., an oncologist at the Greenebaum Cancer Center and assistant professor of medicine at the University of Maryland School of Medicine, is the principal investigator of the newly opened National Cancer Institute-funded study. The trial is based on laboratory studies by Angela H. Brodie, Ph.D., an internationally recognized University of Maryland breast cancer researcher, and her colleagues. Their research, recently published in the journal Cancer Research, found that entinostat can cause triple-negative breast cancer cells to become sensitive to a hormone therapy such as an aromatase inhibitor. Dr. Brodie pioneered the development of aromatase inhibitors, a class of breast cancer drugs that reduces the level of estrogen produced by the body, thereby cutting off the fuel to cancer cells.

In this Phase II trial, doctors will treat newly diagnosed postmenopausal patients with entinostat and an aromatase inhibitor called anastrozole (Arimidex) before they have surgery to remove their cancer. Researchers will analyze tissue from the tumor and blood samples to evaluate whether the treatment is effective. After surgery, patients will receive standard treatment, such as chemotherapy and radiation.

"We hope that entinostat will make the tumor cells more sensitive to the drug anastrozole, causing the tumor to shrink or, at the very least, stop growing," Dr. Chumsri says. "For patients with triple-negative breast cancer, che
'/>"/>

Contact: Karen E. Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. The use of placebo in rheumatoid arthritis clinical trials may negatively impact patients
2. Clinical study suggests estrogen levels and breast health can be altered
3. Progress toward the clinical application of autologous induced pluripotent stem cells and gene repair therapy for treatment of familial hypercholesterolemia
4. New cancer drug discovered at U-M heads to clinical trials
5. JAMIA: Evaluating clinical information systems, patients who use PHRs, how clinicians use EHRs
6. Preview of oral presentations at the 1st IOF-ESCEO Pre-Clinical Symposium
7. Press registration open for clinical nutrition conference
8. Clinical Benefits of Zimmers DeNovo® NT Natural Tissue Graft in First Surgery Documented in Peer-Reviewed Publication
9. Media alert: ACMG 2011 Clinical Genetics Meeting -- press registration is now open
10. MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution
11. UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New clinical trial to test novel approach to treat triple-negative breast cancer
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... food becomes scarce, animal populations exploit a wider range ... at different sites in California,s coastal waters were not ... population is higher where food is limited. But this ... sea otters, which instead showed dietary specialization in response ...
... some of the genetic secrets that enable pine ... disease, uncovering critical new information about forests natural ... this genetic analysis will allow forest stewardship programs ... that could in time repel insects such as ...
... --- Mother Nature regulates critical cellular activities in plants ... specific biochemical reactions. Looking to learn from nature, a ... million grant from the Air Force Office of Scientific ... for military and civilian applications. The grant ...
Cached Biology News:Sea otter study reveals striking variability in diets and feeding strategies 2Sea otter study reveals striking variability in diets and feeding strategies 3UBC discovery unlocks tree genetics, gives new hope for pine beetle defense 2Team of chemists receives $5 million grant to develop enzyme mimics 2
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... Achim Noack has been named global vice president ... position, Noack will assist Jerry Stoller, CEO and president ... and supervise global marketing management and implementation of new ... and experience in the crop protection industry,” says Jerry ... thinking will be a great asset for Stoller Group, ...
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... changes to Martine Rothblatt , Ph.D,s compensation program. ... United Therapeutics announced the promotion of Roger Jeffs ... David Zaccardelli , Pharm.D. to Executive Vice President ... Dr. Rothblatt,s title will change from Chairman and Chief ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... Inc. (Nasdaq: EMIS ) has agreed to ... LLY ) to settle the pending litigation ... submit a Stipulation of Dismissal with,Prejudice of their ... the,Southern District of Indiana. Additional terms and conditions ...
... Morria Biopharmaceuticals Plc, a,private biopharmaceutical company ... announced it has appointed Dr.,Johnson Lau and ... directors. Dr. Johnson Lau (MBBS, MD, ... the,medical, pharmaceutical and corporate fields, having a ...
... f-star, an antibody,engineering company developing novel antibodies ... Antibody Technology, today announced the,appointment of Dr. ... Mudde has,over 20 years of experience in ... research and development. He comes to f-star,from ...
Cached Biology Technology:Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation 2Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors 2Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer 2
... StabilZyme HRP Conjugate Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... 6.7. This product contains a ... 20 ppm Proclin 300 (Rohm and Haas ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... V-106 voice-coil scanning and positioning system ... samples have to be positioned or ... resolution. It provides superior responsiveness compared ... The mechanics (X or XY stage) ...
Biology Products: